OssDsign AB September 26th, 2023 announced a strategic shift to focus its operations on the orthobiologics business in the U.S. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst.

All activities pertaining to the company’s patient-specific cranial implant business will be discontinued in a responsible manner by the end of December 2023.

Read full press release here: